RxDoctor Payments Data

Meghna Chopra, MD

Family Practice · Newport News, VANPI 1295364446

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Novo Nordisk at 28.2% of the total. Reporting peaked in 2024 at $258 and has fallen 56.9% since, to $111 in 2025. Among family practice clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$408in general payments, 2019–2025

Across 20 payments — averaging $20.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$115
  • Amgen$85
  • AbbVie$67
  • Pfizer$37
  • Dexcom, Inc.$34
  • Exact Sciences$33
  • plus $37 from 2 others

What the payments were for

  • Food & beverage$408100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$408 in reported general payments places this provider in the 95th percentile of 508 family practice providers in Virginia.

See all family practice providers in Virginia

Medicare billing

Part B allowed, 2024
$82,202
Medicare patients
190
Services billed
1,347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$21,743
JardianceEmpagliflozin14$14,890
SynthroidLevothyroxine Sodium15$1,327
Albuterol Sulfate HfaAlbuterol Sulfate29$787
Amlodipine Besylate89$779
Atorvastatin Calcium87$694
Levothyroxine Sodium66$547
Bupropion XlBupropion Hcl22$511
Omeprazole51$510
Gabapentin42$485
Tramadol Hcl14$463
Duloxetine Hcl19$446
Pregabalin19$434
Diclofenac Sodium13$404
Metoprolol Succinate30$396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$115$21,74318 claims
AbbVieSynthroid$67$1,32715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 508 family practice providers in Virginia.

Other family practice in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →